Skye Bioscience Inc
SKYE
Get informed when a big investor buys or sells
+ FollowMarket Cap$22.91M
Close$
$0.14
78.3% downside
Current Fair Value
78.3% downsideOvervalued by 78.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $22.91 Million |
|---|---|
| Enterprise Value | $14.82 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.41 |
| Beta | 2.94 |
| Outstanding Shares | 39,681,465 |
Return
| Return on Equity | -636.18% |
|---|---|
| Return on Assets | -295.27% |
| Return on Invested Capital | -17.47% |
Valuation & Multiples
| P/E Ratio | -0.45 |
|---|---|
| PEG | 0.45 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -9.41 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 152.94% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 40.67% |
|---|---|
| Total Invested | $8▼ 100.00% |
| Investors Holding | 3▼ 37.00% |
ESG Score
No data
About Skye Bioscience Inc
11 employees
CEO: Brian Murphy nemus bioscience is a publicly traded, life-science biotech company, developing regulatory-approved, cannabinoid-based therapies, for a spectrum of diseases, especially those of unmet medical need.